SUTENTPISlidekitfinalversionFeb1

1
(No Transcript)
2
SUTENT? (sunitinib malate) capsules

• Access Slide Kit

3
Pfizer Oncology FirstRESOURCE Program Provides
Access to Patients Seeking SUTENT

• Coverage and reimbursement information
• Insurance Benefit Verification, Prior
  Authorization Assistance, Information About Payer
  Policy, Education About Medicare and LIS
  Assistance
• Appeals assistance
• Assistance with appeals process with denied
  claims or coverage
• Assistance with identifying sources of alternate
  coverage
• Referrals to patient support programs
• Patient assistance program
• Assists eligible underinsured and uninsured
  patients gain access to SUTENT

Call FirstRESOURCE at 1-877-744-5675Hours of
Operation 9am to 8pm ET
4

How Will Physicians and Patients Become Aware of
Services, Such as Co-Pay Assistance?
Refer Physicians or Patients to FirstRESOURCE,
If They Are Concerned About Ability to Afford
SUTENT

• FirstRESOURCE Will
• Research and Educate Patients Regarding All
  Available Options for Assistance for Patients
  (including All Co-Pay Foundations)
• Directly Contact the Appropriate Foundations
  Based on the Patients Diagnosis and Need
• Co-Pay Assistance Organizations Will
• Create Awareness Through Marketing and Other
  Initiatives in an Effort to Support the Needs of
  Appropriate Patients

5
Medicare Prescription Drug Programs Coverage of
SUTENT

• Mandatory inclusion of drugs in 6 protected
  classes, including Oncology, is limited to
  treatments available in 2005.
• Medicare Prescription Drug Programs are required
  to review new agents within 90 days of
  availability.
• A final formulary decision needs to be published
  within 180 days of availability
• Pfizer will be providing information on SUTENT to
  healthcare plans shortly after approval.

6
Ongoing SUTENT Studies

• Early data suggest that SUTENT may also have
  activity in other tumor types. Pfizer has
  initiated an extensive clinical research program
  to explore the potential safety and efficacy of
  SUTENT in the treatment of a number of different
  types of cancer.
• A phase III study evaluating the safety and
  efficacy of SUTENT as a first-line treatment for
  metastatic RCC has completed enrollment and data
  collection is ongoing.
• Additional clinical studies are evaluating SUTENT
  as a single agent and in combination with other
  treatments for a number of other solid tumors
• Pfizer also has a clinical trials agreement with
  the National Cancer Institutes (NCI) Cancer
  Therapy Evaluation Program (CTEP) to conduct
  further studies of SUTENT for patients with many
  types of cancers
• Patients and their physicians are encouraged to
  call the SUTENT clinical trial information line
  at 877-416-6248 or to visit the Pfizer Oncology
  Web site (www.pfizeroncology.com) or for more
  information.
• Please see full prescribing information

7
Emerging Med Trial Matching and Referral Service
Links Patients to SUTENT Clinical Trials
Physician/Patient contacts www.PfizerOncology.com
Phone [phone]

• Patient Profile is Matched with Study Criteria

• Patient Selects Trial/Site
• Clinical Trial Specialists Provide Support
• Education
• Navigational Assistance
• Ongoing Counseling